Apoptosis: A link between cancer genetics and chemotherapy

Cell

Volumn 108, Issue 2, 2002, Pages 153-164

  Johnstone, Ricky W ^a   Ruefli, Astrid A ^a   Lowe, Scott W ^b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b Watson School of Biological Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER INVASION; CARCINOGENESIS; CELL DEATH; DRUG ACTIVATION; DRUG DESIGN; DRUG INDUCED DISEASE; DRUG SENSITIVITY; HUMAN; MITOCHONDRION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0037169358     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0092-8674(02)00625-6     Document Type: Review

References (101)

1. Proteasome inhibition in cancer: Development of PS-341
2. The Bcl-2 protein family: Arbiters of cell survival
3. Transgenic models of lymphoid neoplasia and development of a pan-hematopoietic vector
4. c-Myc/p53 interaction determines sensitivity of human colon carcinoma cells to 5-fluorouracil in vitro and in vivo
5. Safety and antitumor activity of recombinant soluble Apo2 ligand
6. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells
7. The role of p53 in tumour suppression: Lessons from mouse models
8. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB
9. p53 upregulates cFLIP, inhibits transcription of NF-κB-regulated genes and induces caspase-8-independent cell death in DLD-1 cells
10. Stress management - Heat shock protein-70 and the regulation of apoptosis
11. Unwinding the loop of Bcl-2 phosphorylation
12. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms
13. Apoptosis, p53, and tumor cell sensitivity to anticancer agents
14. Disruption of p53 in human cancer cells alters the responses to therapeutic agents
15. Induction of apoptosis in 9-nitrocamptothecin-treated DU145 human prostate carcinoma cells correlates with de novo synthesis of CD95 and CD95 ligand and down-regulation of c-FLIP(short)
16. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists
17. Bcl-2, bcl-x(l) sequester bh3 domain-only molecules preventing bax- and bak-mediated mitochondrial apoptosis
18. p53-dependent and -independent links between DNA-damage, apoptosis and mutation frequency in ES cells
19. Heat shock proteins - Modulators of apoptosis in tumour cells
20. A phase I trial of H-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma
21. Oncogenic alterations of metabolism
22. Cellular survival: A play in three Akts
23. IAP family proteins-suppressors of apoptosis
24. The multiple roles of PTEN in tumor suppression
25. Systemic overexpression of BCL-2 in the hematopoietic system protects transgenic mice from the consequences of lethal irradiation
26. Role of oncogenes in resistance and killing by cancer therapeutic agents
27. Proliferation, cell cycle and apoptosis in cancer
28. Critical determinants of cancer metastasis: Rationale for therapy
29. Pharmacological rescue of mutant p53 conformation and function
30. Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis
31. Apoptotic pathways: Paper wraps stone blunts scissors
32. Absence of p53 permits propagation of mutant cells following genotoxic damage
33. Inactivation of the retinoblastoma tumor suppressor induces apoptosis protease-activating factor-1 dependent and independent apoptotic pathways during embryogenesis
34. The hallmarks of cancer
35. p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD
36. Rb function in cell-cycle regulation and apoptosis
37. Cellular stress response and apoptosis in cancer therapy
38. Transcriptional repression of the anti-apoptotic surviving gene by wild type p53
39. BH3-only proteins-essential initiators of apoptotic cell death
40. Ferredoxin reductase affects p53-dependent, 5-fluorouracil-induced apoptosis in colorectal cancer cells
41. Small cell lung cancer
42. Chemosensitisation of malignant melanoma by BCL2 antisense therapy
43. Apaf-1 protein deficiency confers resistance to cytochrome c-dependent apoptosis in human leukemic cell
44. Multiple physiological functions for multidrug transporter P-glycoprotein?
45. DNA double-strand breaks: Signaling, repair and the cancer connection
46. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy
47. Suppression of p53: A new approach to overcome side effects of antitumor therapy
48. Chemoprotection from p53-dependent apoptosis: Potential clinical applications of the p53 inhibitors
49. Mutations of the bak gene in human gastric and colorectal cancers
50. Cyclin A-kinase regulation of E2F-1 DNA binding function underlies suppression of an S phase checkpoint
51. The incidence of secondary leukemias
52. Overexpression of Bcl-x(L) promotes chemotherapy resistance of mammary tumors in a syngeneic mouse model
53. The role of caspases in development, immunity, and apoptotic signal transduction: Lessons from knockout mice
54. Apoptosis in cancer
55. Histone deacetylase inhibitors as new cancer drugs
56. Breaking the mitochondrial barrier
57. Apaf-1 is a transcriptional target for E2F and p53
58. Defining CD95 as a tumor suppressor gene
59. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells
60. Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor
61. DNA methylation in genomic imprinting, development, and disease
62. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype
63. Dysregulation of apoptosis in cancer
64. The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53
65. Tumor immunity in perforin-deficient mice: A role for CD95 (Fas/APO-1)
66. Phosphatidylinositol 3-kinases in tumor progression
67. Role of NF-kappaB in p53-mediated programmed cell death
68. Regulation and function of p53 tumor suppressor protein
69. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells
70. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53
71. Genetic analysis of chemoresistance in primary murine lymphomas
72. The ARF/p53 pathway
73. Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers
74. Bcl-2 with loss of apoptosis allows accumulation of genetic alterations: A pathway to metastatic progression in human breast cancer
75. Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition
76. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma
77. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
78. Regulation of PTEN transcription by p53
79. The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis
80. A serine protease, Htra2, is released from the mitochondria and interacts with xiap, inducing cell death
81. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer
82. In vivo cytotoxicity of ovarian cancer cells through tumor-selective expression of the BAX gene
83. Telomerase activation by histone deacetylase inhibitor in normal cells
84. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells
85. Antisense therapy in oncology: New hope for an old idea?
86. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN
87. Modulation of caspase-8 and FLICE-inhibitory protein expression as a potential mechanism of Epstein-Barr virus tumorigenesis in Burkitt's lymphoma
88. Proapoptotic functions of cytotoxic lymphocyte granule constituents in vitro and in vivo
89. Surfing the p53 network
90. Multidrug resistance and its reversal
91. Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-xL-overexpressing chemotherapy-resistant tumor cells
92. Germinal center-derived signals act with Bcl-2 to decrease apoptosis and increase clonogenicity of drug-treated human B lymphoma cells
93. Clinical implications of p53 mutations
94. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells
95. The expanding role of mitochondria in apoptosis
96. Cytochrome c maintains mitochondrial transmembrane potential and ATP generation after outer mitochondrial membrane permeabilization during the apoptotic process
97. Proapoptotic BAX and BAK: A requisite gateway to mitochondrial dysfunction and death
98. Defective cytochrome c-dependent caspase activation in ovarian cancer cell lines due to diminished or absent apoptotic protease activating factor-1 activity
99. Negative regulation of bcl-2 expression by p53 in hematopoietic cells
100. p63 and p73: p53 mimics, menaces and more
101. Role of BAX in the apoptotic response to anticancer agents